Barbara Pro

17.2k total citations · 5 hit papers
289 papers, 9.9k citations indexed

About

Barbara Pro is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Barbara Pro has authored 289 papers receiving a total of 9.9k indexed citations (citations by other indexed papers that have themselves been cited), including 236 papers in Pathology and Forensic Medicine, 137 papers in Oncology and 85 papers in Genetics. Recurrent topics in Barbara Pro's work include Lymphoma Diagnosis and Treatment (234 papers), Chronic Lymphocytic Leukemia Research (84 papers) and Viral-associated cancers and disorders (54 papers). Barbara Pro is often cited by papers focused on Lymphoma Diagnosis and Treatment (234 papers), Chronic Lymphocytic Leukemia Research (84 papers) and Viral-associated cancers and disorders (54 papers). Barbara Pro collaborates with scholars based in United States, France and Italy. Barbara Pro's co-authors include Peter McLaughlin, Luis Fayad, Anas Younes, Jorge Romaguera, Andrei R. Shustov, Felipe Samaniego, Maria Alma Rodriguez, André Goy, Nam H. Dang and Fernando Cabanillas and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Barbara Pro

282 papers receiving 9.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

2012 711 citations Barbara Pro, Ranjana H. Advani et al. Journal of Clinical Oncology profile →
Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project

2009 506 citations Massimo Federico, Monica Bellei et al. Journal of Clinical Oncology profile →
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

2012 485 citations Bertrand Coiffier, Barbara Pro et al. Journal of Clinical Oncology profile →
Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

2011 439 citations Owen A. O’Connor, Barbara Pro et al. Journal of Clinical Oncology profile →
Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins

2013 384 citations Luis Fayad, Barbara Pro et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Barbara Pro	6.8k	5.3k	2.4k	2.2k	1.7k	289	9.9k
Won Seog Kim	7.1k 1.0×	6.3k 1.2×	3.0k 1.3×	1.8k 0.8×	873 0.5×	462	10.8k
Luis Fayad	6.3k 0.9×	5.5k 1.0×	1.7k 0.7×	2.7k 1.2×	1.1k 0.6×	334	9.7k
German Ott	8.7k 1.3×	6.2k 1.2×	2.0k 0.8×	4.0k 1.8×	906 0.5×	336	12.9k
Armando López‐Guillermo	8.4k 1.2×	5.2k 1.0×	2.4k 1.0×	4.4k 2.0×	779 0.5×	244	11.5k
Eric D. Hsi	6.0k 0.9×	4.7k 0.9×	2.6k 1.1×	3.5k 1.6×	1.2k 0.7×	405	12.2k
Paul J. Kurtin	5.1k 0.8×	3.6k 0.7×	2.2k 0.9×	2.8k 1.3×	995 0.6×	235	11.4k
Daphne de Jong	5.8k 0.9×	4.4k 0.8×	1.7k 0.7×	2.0k 0.9×	610 0.4×	214	10.3k
Kerry J. Savage	10.6k 1.6×	7.4k 1.4×	2.8k 1.2×	3.0k 1.4×	1.8k 1.0×	305	13.4k
Steven M. Horwitz	4.8k 0.7×	3.1k 0.6×	2.1k 0.9×	1.3k 0.6×	1.5k 0.9×	239	7.0k
Josette Brière	10.0k 1.5×	7.4k 1.4×	2.4k 1.0×	3.3k 1.5×	1.1k 0.6×	190	13.6k

Countries citing papers authored by Barbara Pro

Since Specialization

Citations

This map shows the geographic impact of Barbara Pro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Pro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Pro more than expected).

Fields of papers citing papers by Barbara Pro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Pro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Pro. The network helps show where Barbara Pro may publish in the future.

Co-authorship network of co-authors of Barbara Pro

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Pro. A scholar is included among the top collaborators of Barbara Pro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Pro. Barbara Pro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tolu, Seda S., et al.. (2025). Ruxolitinib increases immunogenicity and primes the tumor microenvironment for immune checkpoint blockade in 9p24.1 amplified lymphomas. Blood. 146(Supplement 1). 3558–3558.

Tolu, Seda S., Caitlin Gribbin, Zhengming Chen, et al.. (2025). Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents. Leukemia & lymphoma. 66(13). 2437–2447.

Zinzani, Pier Luigi, Eric D. Jacobsen, Jasmine Zain, et al.. (2024). Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial. Blood. 144(Supplement 1). 3061–3061. 4 indexed citations

Ruan, Jia, Jasmine M. Zain, Borko Jovanovic, et al.. (2023). Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma. Blood Advances. 7(19). 5771–5779. 19 indexed citations

Poon, Limei, Laurence de Leval, Siok‐Bian Ng, et al.. (2023). Hematological Oncology journal women in lymphoma special issue: Latest updates in nodal peripheral T‐cell lymphoma. Hematological Oncology. 42(6). e3191–e3191. 2 indexed citations

Quaglino, Pietro, Nicola Pimpinelli, Pier Luigi Zinzani, et al.. (2023). Identifying and addressing unmet clinical needs in primary cutaneous B‐cell lymphoma: A consensus‐based paper from an ad‐hoc international panel. Hematological Oncology. 42(1). e3215–e3215. 1 indexed citations

Lansigan, Frederick, Sarah McCue Horwitz, Lauren Pinter‐Brown, et al.. (2020). Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study. Clinical Lymphoma Myeloma & Leukemia. 20(11). 744–748. 9 indexed citations

Stuver, Robert, Niloufer Khan, Marc Schwartz, et al.. (2019). Single agents vs combination chemotherapy in relapsed and refractory peripheral T‐cell lymphoma: Results from the comprehensive oncology measures for peripheral T‐cell lymphoma treatment (COMPLETE) registry. American Journal of Hematology. 94(6). 641–649. 27 indexed citations

Paudel, N, et al.. (2018). Radiation Oncology Education for Medical Oncology Fellowship Trainees: A Pilot Needs Assessment. International Journal of Radiation Oncology*Biology*Physics. 102(3). e395–e395. 1 indexed citations

10.

Fanale, Michelle A., Sarah McCue Horwitz, Andres Forero‐Torres, et al.. (2017). Five-Year Survival Results: Frontline Brentuximab Vedotin in Combination with CHP in Patients with CD30-Expressing Peripheral T-Cell Lymphomas. Blood. 130. 2790–2790. 3 indexed citations

11.

Zinzani, Pier Luigi, Max S. Topp, Sam Yuen, et al.. (2016). Phase 2 Study of Venetoclax Plus Rituximab or Randomized Ven Plus Bendamustine+Rituximab (BR) Versus BR in Patients with Relapsed/Refractory Follicular Lymphoma: Interim Data. Blood. 128(22). 617–617. 23 indexed citations

12.

Advani, Ranjana H., Stephen M. Ansell, Mary Jo Lechowicz, et al.. (2015). A phase II study of cyclophosphamide, etoposide, vincristine and prednisone ( CEOP ) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T‐cell lymphoma ( PTCL ): final results from the T‐ cell consortium trial. British Journal of Haematology. 172(4). 535–544. 66 indexed citations

13.

Horwitz, Sarah McCue, Bertrand Coiffier, Francine M. Foss, et al.. (2015). Utility of18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma. Annals of Oncology. 26(4). 774–779. 12 indexed citations

14.

Hagemeister, Fredrick B., Maria Alma Rodriguez, Steven R. Deitcher, et al.. (2013). Long term results of a phase 2 study of vincristine sulfate liposome injection ( M arqibo ^® ) substituted for non‐liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non‐ H odgkin lymphomas. British Journal of Haematology. 162(5). 631–638. 24 indexed citations

15.

Coiffier, Bertrand, Barbara Pro, H. Miles Prince, et al.. (2012). Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy. Journal of Clinical Oncology. 30(6). 631–636. 485 indexed citations breakdown →

16.

Solal‐Céligny, Philippe, Monica Bellei, Luigi Marcheselli, et al.. (2012). Watchful Waiting in Low–Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database. Journal of Clinical Oncology. 30(31). 3848–3853. 88 indexed citations

17.

O’Connor, Owen A., Barbara Pro, Lauren Pinter‐Brown, et al.. (2011). Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study. Journal of Clinical Oncology. 29(9). 1182–1189. 439 indexed citations breakdown →

18.

Wang, Michael, Yasuhiro Oki, Barbara Pro, et al.. (2009). Phase II Study of Yttrium-90–Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma. Journal of Clinical Oncology. 27(31). 5213–5218. 66 indexed citations

19.

Christie, David, Elías Gracia, M. Gospodarowicz, et al.. (2007). Patterns of outcome and prognostic factors in primary bone lymphoma (osteolymphoma): A survey of 499 cases by the international extranodal lymphoma study group. Haematologica. 92. 3 indexed citations

20.

Rodriguez, Maria Alma, Fernando Cabanillas, Nam H. Dang, et al.. (2004). Recovery of natural killer cell counts after one course of CHOP chemotherapy is diminished in patients older than 60 compared to patients younger than 60.. Cancer Research. 64. 507–507. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact